65 Equity Partners makes first European deal with HAS

The firm will also back HAS’ planned acquisition of Cerbios-Pharma.

  • 65 Equity will hold around 40% stake in the combined company
  • HAS develops and produces APIs, HPAPIs and anticancer compounds
  • Cerbios-Pharma manufactures chemical and biological APIs

65 Equity Partners has invested in HAS Healthcare Advanced Synthesis, an international developer and producer of active pharmaceutical ingredients (APIs), high-potency active pharmaceutical ingredients (HPAPIs) and anticancer compounds.

Share this